ArticleThe Journal of clinical investigation2013

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Paolo Neviani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.